Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more
Jagsonpal Pharmaceuticals Limited - Asset Resilience Ratio
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has an Asset Resilience Ratio of 49.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Jagsonpal Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Jagsonpal Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0% |
| Short-term Investments | ₹1.47 Billion | 49.0% |
| Total Liquid Assets | ₹1.47 Billion | 49.00% |
Asset Resilience Insights
- Very High Liquidity: Jagsonpal Pharmaceuticals Limited maintains exceptional liquid asset reserves at 49.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jagsonpal Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Jagsonpal Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Jagsonpal Pharmaceuticals Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Jagsonpal Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 42.23% | ₹1.18 Billion | ₹2.78 Billion | -20.04pp |
| 2024-03-31 | 62.27% | ₹1.35 Billion | ₹2.17 Billion | +3.31pp |
| 2023-03-31 | 58.96% | ₹1.15 Billion | ₹1.95 Billion | +30.61pp |
| 2022-03-31 | 28.35% | ₹477.64 Million | ₹1.68 Billion | -9.52pp |
| 2021-03-31 | 37.88% | ₹621.94 Million | ₹1.64 Billion | +8.57pp |
| 2020-03-31 | 29.30% | ₹430.64 Million | ₹1.47 Billion | +6.24pp |
| 2019-03-31 | 23.06% | ₹313.12 Million | ₹1.36 Billion | +16.59pp |
| 2018-03-31 | 6.47% | ₹83.98 Million | ₹1.30 Billion | -14.95pp |
| 2017-03-31 | 21.42% | ₹305.53 Million | ₹1.43 Billion | -- |